ArticleInternational journal of cancer2026
Pubertal timing and incident uterine cancer in the Sister Study cohort.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Younger age at menarche is an established uterine cancer risk factor. Age at onset of breast development (thelarche), the earliest marker of pubertal "unopposed" estrogen exposure, may also be relevant to uterine cancer risk, particularly considering rapid declines in age at thelarche over time in parallel with increasing uterine cancer incidence rates. Using data from 34,152 participants with an intact uterus when they enrolled in the US Sister Study cohort (2003-2009; ages 35-74 years), we examined associations of self-reported ages at thelarche and menarche with incident uterine cancer using multivariable-adjusted Cox proportional hazards regression. We stratified by birth cohort, race, weight relative to peers in childhood, and body mass index (BMI) at enrollment to explore potential effect measure modification and tested for statistical heterogeneity across strata. During follow-up (median = 13.3 years), 445 women reported an incident uterine cancer diagnosis. Ages at thelarche (hazard ratio [HR] per 1-year older: 0.91, 95% confidence interval [CI]: 0.85-0.97) and menarche (HR per 1-year older: 0.90, 95% CI: 0.84-0.96) were inversely associated with uterine cancer incidence. Associations were similar in non-Hispanic Black and White women and did not vary by relative childhood weight or BMI in adulthood. Inverse associations of thelarche and menarche were limited to women born in 1950 or later (p-het <.05). These findings suggest that younger ages at thelarche and menarche, markers of earlier and potentially prolonged exposure to estrogen in the absence of progesterone during puberty, may enhance susceptibility to uterine carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.